You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PIK3CA MT

Showing 1 - 25 of 2,220
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

Active, not recruiting
  • HER2-positive Breast Cancer
  • PIK3CA analysis
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)

Completed
  • PIK3CA Mutation-Related Tumors
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Nov 9, 2023

Lymphatic Malformations Trial (Alpelisib, Placebo)

Not yet recruiting
  • Lymphatic Malformations
  • (no location specified)
Jul 4, 2023

Patterns Among PIK3CA Mutation in Advanced Breast Cancer

Completed
  • Breast Cancer
    • East Hanover, New Jersey
      Novartis
    Aug 1, 2023

    PIK3CA-Related Overgrowth Spectrum (PROS) Trial in Worldwide (alpelisib)

    Available
    • PIK3CA-Related Overgrowth Spectrum (PROS)
    • (no location specified)
    Sep 9, 2022

    Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (MEN1611, Eribulin)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • (no location specified)
    Apr 12, 2023

    HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

    Recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Targeted Therapy
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Aug 1, 2023

    Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

    Not yet recruiting
    • PIK3CA-related Overgrowth Spectrum
    • +8 more
    • national registry
    • Paris, France
      Translational medicine and Targeted therapies unit, Hôpital Neck
    Sep 28, 2022

    Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

    Recruiting
    • Endometrial Cancer
    • Ovarian Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 27, 2022

    HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)

    Recruiting
    • HER2-positive Metastatic Breast Cancer
    • Aurora, Colorado
    • +2 more
    Dec 29, 2022

    Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 30, 2023

    Health-related Quality of Life, Symptom Severity, and Pain Among

    Recruiting
    • PIK3CA-related Overgrowth Spectrum
    • Alpelisib
    • East Hanover, New Jersey
      Novartis Investigative Site
    Jun 14, 2022

    A NIS of Alpelisib in Combination With Fulvestrant in

    Not yet recruiting
    • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
    • Alpelisib
    • Fulvestrant
    • (no location specified)
    Aug 9, 2022

    Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)

    Recruiting
    • Advanced Breast Cancer
    • Thalassery, Kerala, India
      Novartis Investigative Site
    Nov 21, 2022

    Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in

    Recruiting
    • Hormone Receptor Positive Breast Carcinoma
    • +2 more
    • Chicago, Illinois
    • +2 more
    Jul 1, 2022

    PIK3CA E545A Trial (Glycopyrrolate, Anisodamine)

    Not yet recruiting
    • PIK3CA E545A
    • (no location specified)
    Sep 17, 2023

    HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • (no location specified)
    Mar 23, 2022

    Advanced Breast Cancer Trial in Orebro (Alpelisib, fulvestrant)

    Terminated
    • Advanced Breast Cancer
    • Orebro, Sweden
    • +1 more
    Nov 21, 2022

    Metastatic Breast Cancer Trial (Inavolisib, Phesgo, Placebo)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Jun 7, 2023

    Tolerability Outcomes of Alpelisib in Real-world

    Recruiting
    • Breast Cancer
    • alpelisib plus fulvestrant
    • Mumbai, Maharashtra, India
    • +3 more
    Jun 8, 2022

    PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome Trial in Worldwide (Miransertib)

    Terminated
    • PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
    • Atlanta, Georgia
    • +10 more
    May 10, 2022

    PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

    Not yet recruiting
    • PIK3CA Mutation
    • +7 more
    • (no location specified)
    Mar 7, 2023

    Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation Trial in United States (Serabelisib, Insulin Suppressing

    Recruiting
    • Advanced Solid Tumor
    • +2 more
    • Birmingham, Alabama
    • +9 more
    May 25, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Biopsy
    • +3 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Aug 5, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Feb 4, 2022